Allergan (NYSE:AGN) announces a quarterly dividend of $0.74



Allergan (NYSE:AGN) to go ex-dividend.
On 1/25/2019 Allergan ( NYSE:AGN ) announced that it will be issuing a quarterly dividend in the amount of $0.74 down from $0.74 making the yield 1.88%.


Allergan (NYSE:AGN) Ex- dividend date

Allergan (NYSE:AGN) is set to go ex-dividend on and will be payable on 3/15/2019


Dividend History for Allergan (NYSE:AGN)
The next payable dividend for Allergan is scheduled for 3/15/2019. There is an annual dividend of $$2.88 with a yield of 1.80% The company’s dividend has increased by 286.20% on a 3 Year Average

Recent Dividend History for Allergan (NYSE:AGN)

  • On 2/6/2013 Allergan announced a quarterly dividend of $0.05.
  • On 5/2/2013 Allergan announced a quarterly dividend of $0.05.
  • On 7/31/2013 Allergan announced a quarterly dividend of $0.05.
  • On 10/30/2013 Allergan announced a quarterly dividend of $0.05.
  • On 2/5/2014 Allergan announced a quarterly dividend of $0.05.
  • On 5/7/2014 Allergan announced a quarterly dividend of $0.05.
Story continues below



About Company
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. It also provides breast implants and tissue expanders; RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis; ocular implants; and Kybella, a non-surgical treatment for submental fullness. In addition, the company develops therapies for non-alcoholic steatohepatitis and other liver diseases; treatments for neurodegenerative disorders, including Alzheimer's disease; small molecule therapeutics that target inflammatory and fibrotic diseases; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and licensing agreements with Assembly Biosciences, Inc. MedImmune, and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Recent Insider Trading for Allergan (NYSE:AGN)

  • On 11/16/2018 Matthew M. Walsh, CFO, bought 1,000 with an average share price of $157.00 per share and the total transaction amounting to $157,000.00.
  • On 9/6/2018 Christopher J. Coughlin, Director, bought 10,000 with an average share price of $190.64 per share and the total transaction amounting to $1,906,400.00.
  • On 8/30/2018 Joseph H. Boccuzi, Director, bought 900 with an average share price of $190.59 per share and the total transaction amounting to $171,531.00.
  • On 5/17/2018 William Meury, EVP, sold 24,425 with an average share price of $154.59 per share and the total transaction amounting to $3,775,860.75.
  • On 3/15/2018 Maria Teresa Hilado, Insider, bought 895 with an average share price of $167.39 per share and the total transaction amounting to $149,814.05.
  • On 3/8/2018 Brent L. Saunders, CEO, bought 3,300 with an average share price of $152.53 per share and the total transaction amounting to $503,349.00.



Recent Analyst Rating for Allergan (NYSE:AGN)

  • On 1/8/2019 Credit Suisse Group, Lower Price Target, fromOutperform to Outperform with a price target of $200.00 to $197.00
  • On 1/4/2019 Cantor Fitzgerald, Set Price Target, to Hold with a price target of $180.00
  • On 12/20/2018 Morgan Stanley, Set Price Target, to bought with a price target of $183.00
  • On 11/30/2018 Royal Bank of Canada, Set Price Target, to bought with a price target of $220.00
  • On 11/12/2018 Leerink Swann, Initiated Coverage, to Outperform with a price target of $220.00
  • On 10/31/2018 Wells Fargo & Co, Reiterated Rating, to bought



Recent Trading for Allergan (NYSE:AGN)
Shares of Allergan closed the previous trading session at with 158.58 shares trading hands.

An ad to help with our costs